CCO Independent Conference Coverage
CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*
October 25-28, 2008 | Washington, DC
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Timing and Choice of First-Line Antiretroviral Therapy
|
Track 1 of 6
|
|
|
|
   |
- Joel E. Gallant, MD, MPH
- W. David Hardy, MD
- Kathleen E. Squires, MD
|
|
|
Management of Treatment-Experienced Patients
|
Track 2 of 6
|
|
|
|
   |
- Eric S. Daar, MD
- Joseph J. Eron, Jr., MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Clinical Complications of HIV and Its Therapy
|
Track 3 of 6
|
|
|
|
   |
- Judith S. Currier, MD, MSc
- Donald P. Kotler, MD
- William G. Powderly, MD
|
|
|
Hepatitis and Opportunistic Coinfections
|
Track 4 of 6
|
|
|
|
   |
- Richard E. Chaisson, MD
- Sally Hodder, MD
- Bruce Polsky, MD
|
|
|
Overview of the 2008 ICAAC/IDSA Annual Meeting
|
Track 6 of 6
|
Expert Highlights
Choose a highlight from the list below:
|
Antiretroviral Therapy in Treatment-Naive Patients
Anton L. Pozniak, MD, FRCP, reports on the 96-week results from the CASTLE, ARTEMIS, and HEAT clinical trials in treatment-naive patients as well as several analyses on the use of abacavir in patients with high HIV-1 RNA.
 Audio File 7.85 MB
|
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
No Improvement in TB Disease-Free Survival With Isoniazid Prophylaxis Among HIV-Infected Children in Sub-Saharan Africa
High overall incidence of TB among HIV-infected infants in both isoniazid and placebo treatment groups, yet childhood-related infections not associated with TB were primary causes of death
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|